CL2021002149A1 - Formulación de afabicin, método para elaborar la misma - Google Patents

Formulación de afabicin, método para elaborar la misma

Info

Publication number
CL2021002149A1
CL2021002149A1 CL2021002149A CL2021002149A CL2021002149A1 CL 2021002149 A1 CL2021002149 A1 CL 2021002149A1 CL 2021002149 A CL2021002149 A CL 2021002149A CL 2021002149 A CL2021002149 A CL 2021002149A CL 2021002149 A1 CL2021002149 A1 CL 2021002149A1
Authority
CL
Chile
Prior art keywords
afabicin
elaborate
formulation
same
compositions
Prior art date
Application number
CL2021002149A
Other languages
English (en)
Inventor
Marie Decrette
Aude Anne-Laure Colin
Sebastien Chabaud
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of CL2021002149A1 publication Critical patent/CL2021002149A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona composiciones farmacéuticas sólidas que contienen Afabicin que presentan características de disolución superiores. Este efecto beneficioso se logra mediante la presencia de un compuesto de histidina para fabricar las composiciones. La presente invención proporciona además métodos para preparar tales composiciones y usos de las mismas.
CL2021002149A 2019-02-14 2021-08-13 Formulación de afabicin, método para elaborar la misma CL2021002149A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19157255 2019-02-14

Publications (1)

Publication Number Publication Date
CL2021002149A1 true CL2021002149A1 (es) 2022-03-04

Family

ID=65440901

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002149A CL2021002149A1 (es) 2019-02-14 2021-08-13 Formulación de afabicin, método para elaborar la misma

Country Status (27)

Country Link
US (1) US20220142993A1 (es)
EP (1) EP3923914B1 (es)
JP (1) JP7383715B2 (es)
KR (1) KR20210127187A (es)
CN (2) CN113423390B (es)
AU (1) AU2020223515A1 (es)
BR (1) BR112021015825B1 (es)
CA (1) CA3129508A1 (es)
CL (1) CL2021002149A1 (es)
CY (1) CY1126077T1 (es)
DK (1) DK3923914T3 (es)
EA (1) EA202192246A1 (es)
ES (1) ES2944535T3 (es)
FI (1) FI3923914T3 (es)
HR (1) HRP20230437T1 (es)
HU (1) HUE062061T2 (es)
IL (1) IL285204A (es)
LT (1) LT3923914T (es)
MA (1) MA54009B1 (es)
MX (1) MX2021009799A (es)
PL (1) PL3923914T3 (es)
PT (1) PT3923914T (es)
RS (1) RS64158B1 (es)
SG (1) SG11202108591PA (es)
SI (1) SI3923914T1 (es)
TN (1) TN2021000159A1 (es)
WO (1) WO2020165407A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202106061VA (en) 2018-12-21 2021-07-29 Acurx Pharmaceuticals Llc Dna polymerase iiic inhibitors and use thereof
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60230934D1 (de) * 2001-04-06 2009-03-05 Affinium Pharm Inc Fab-i-inhibitoren
CN101415701A (zh) * 2005-12-05 2009-04-22 Affinium医药公司 作为fabi抑制剂的杂环丙烯酰胺化合物和抗菌剂
EP2861608B8 (en) 2012-06-19 2019-06-19 Debiopharm International SA Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
JP6998881B2 (ja) 2016-02-26 2022-02-10 デビオファーム・インターナショナル・エス・アー 糖尿病性足感染症の処置のための医薬

Also Published As

Publication number Publication date
US20220142993A1 (en) 2022-05-12
EP3923914A1 (en) 2021-12-22
CN113423390A (zh) 2021-09-21
FI3923914T3 (fi) 2023-04-27
BR112021015825B1 (pt) 2024-03-12
JP2022520170A (ja) 2022-03-29
RS64158B1 (sr) 2023-05-31
IL285204A (en) 2021-09-30
CA3129508A1 (en) 2020-08-20
JP7383715B2 (ja) 2023-11-20
AU2020223515A1 (en) 2021-08-19
EP3923914B1 (en) 2023-04-12
MX2021009799A (es) 2021-09-08
CN116327781A (zh) 2023-06-27
PT3923914T (pt) 2023-05-04
CY1126077T1 (el) 2023-11-15
HRP20230437T1 (hr) 2023-07-07
BR112021015825A2 (pt) 2021-10-13
MA54009B1 (fr) 2022-10-31
SI3923914T1 (sl) 2023-08-31
PL3923914T3 (pl) 2023-08-07
KR20210127187A (ko) 2021-10-21
LT3923914T (lt) 2023-07-25
MA54009A1 (fr) 2022-05-31
TN2021000159A1 (en) 2023-04-04
CN113423390B (zh) 2023-05-23
ES2944535T3 (es) 2023-06-22
EA202192246A1 (ru) 2021-11-18
HUE062061T2 (hu) 2023-09-28
WO2020165407A1 (en) 2020-08-20
SG11202108591PA (en) 2021-09-29
DK3923914T3 (da) 2023-05-01

Similar Documents

Publication Publication Date Title
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
CL2016003048A1 (es) Analogos de panonina minimas sintesis y uso de los mismos.
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
CL2021002149A1 (es) Formulación de afabicin, método para elaborar la misma
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
MX2018015302A (es) Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos.
EA202090448A1 (ru) Дигидрооксадиазиноны
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CR20160433A (es) Nuevos compuestos
CL2018001210A1 (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico.
BR112018006730A2 (pt) método para preparar um composto, substância ou mistura de substância, uso de pelo menos uma substância ou mistura de substância, composição de fragrância, e, agente.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
EA201992509A1 (ru) Гетероарилфениламинохинолины и аналоги
PH12016500414B1 (en) Solid preparation containing choline alfoscerate and method for preparing same
BR112018070626A2 (pt) formulação farmacêutica, e, composto ou composição para uso, uso, método ou composição
MY185605A (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
CU20160139A7 (es) Benzamidas y anilidas sustituidas en calidad de inhibidores de las vías de de señalización wnt, las composiciones y combinaciones farmacéuticas que las comprenden, y los compuestos intermediarios útiles para preparar estos compuestos
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CL2020002519A1 (es) Composiciones de erenumab y usos de las mismas
BR112019000486A2 (pt) composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar psoríase